Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Transcription

1 Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

2

3

4

5

6 Size of Components of Human Genome Size of haploid genome! Estimated genetic constitution! Size of average chromosome band! Size of average gene 3.3 X 10 9 DNA basepairs 30,000 genes 3 X 10 6 DNA basepairs 5 X 10 4 DNA basepairs

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36 Mitotic events affecting chromosomes in neoplastic cells: Abnormal segregation Chromosome breakage

37

38 60,XY,+X,+Y,+2,+5,+6,+7,+8,+13,+16,+17,+19,+21,+21,+22

39

40

41

42

43

44

45

46

47

48 46,XX,t(9;22)(q34;q11.2)

49

50

51

52 48,XX,+8,+8,t(9;11)(p22;q23)

53

54

55

56 46,XX,+7,t(8;14)(q24;q32),der(13)t(1;13)(q21;p12),-19

57

58 Secondary Leukemia! Alkylating agents and/or radiation -5/del(5q) -7/del(7q)

59

60 Secondary Leukemia! Epipodophyllotoxins / Anthracyclines t(11q23) (MLL) t(21q22) (CBFA2)

61

62 Overall AML survival by cytogenetics Slovak ML et al Blood 96: , 2000

63 Mrozek K et al Blood 2007: 109: Pie chart based on 246 patients analyzed for the presence or absence of mutations in the NPM1 and CEBPA genes, FLT3- ITD, FLT3-TKD, and MLL-PTD indicating the coexistence of mutations in individual patients. WT indicates patients with only wild-type alleles of genes tested. Adapted by Kenneth X. Probst from Döhner et al with permission.

64 Proposed schema assigning AML patients with a normal karyotype to riskadapted postremission therapies using information on currently known prognostic markers as a basis for designing future clinical studies. SCT denotes stem-cell transplantation; ASCT, autologous SCT; and HDAC, high-dose cytarabine. Illustration drawn by Kenneth X. Probst. Mrozek K et al Blood 2007: 109:

65 CYTOGENETIC MECHANISMS IN SOLID TUMORS Deletions Translocations Amplifications

66

67

68 Solid Tumor Cytogenetics: art or science? 1. Unpredictable growth of the neoplastic cells in tissue culture.

69 Solid Tumor Cytogenetics: art or science? 2. Overgrowth of neoplastic cells by reactive non-neoplastic cells.

70 Solid Tumor Cytogenetics: art or science? 3. Destruction of tumor cultures by bacterial or fungal infection.

71 Solid Tumor Cytogenetics: art or science? 4. Failure of tumor cultures to grow because of non-viable tumor.

72

73

74

75 Chromosome translocations in cancer: Gene fusion Gene activation

76 Chromosome abnormalities in cancer Acquired Nonrandom Clonal Used for diagnosis and prognosis

77 Chromosome Changes in Cancer Disease specific changes: Leukemias Lymphomas Mesenchymal Tumors

78 Chromosome Changes in Cancer Unbalanced multiple and unspecific karyotypic abnormalities: Epithelial tumors (breast, colon, lung, prostate, ovary) Mesenchymal tumors (osteosarcoma, malignant fibrous histiocytoma) Secondary hematologic malignancies

79 Functional Consequences of Balanced Chromosomal Rearrangements Fröhling S, Döhner H. N Engl J Med 2008;359:

80 Molecular Cytogenetics

81 Fluorescence in situ Hybridization (FISH)

82 Fluorescence in situ Hybridization (FISH) Hybridization of a fluorescently labeled nucleic acid probe to a target sequence within a specimen on a microscope slide

83 Basic FISH Procedure Prepare Slide (denature, dehydrate) Prepare Probe (denature in hyb. buffer) Hybridize Wash Counterstain (with DAPI-antifade) Visualize

84

85 Visualizing FISH Emission / Barrier Filter Dichroic Mirror Excitation Filter

86

87 FISH in the cytogenetics laboratory: Satellite sequence probes Whole chromosome paints Unique sequence probes

88

89 Molecular Cytogenetic Analysis In situ Hybridization Targets Metaphase chromosomes Interphase nuclei Formalin-fixed, paraffin-embedded tissues

90 FISH Overview Each probe attaches to specific target. Differently colored probes simultaneously determine both number and location of different loci. Metaphase & interphase Quantitative assessment in intact tissue, cells, nuclei or chromosomes.

91

92 FISH Probe Design & Patterns for Detection of Chromosome Translocations & Inversions Dual Color, Single Fusion Dual Color, ES (extra signal) Dual Color, Break-Apart Dual Color, Dual Fusion

93 Dual Color, Break-apart: Both Probes Flank One Breakpoint 14q32.33 IGH Locus Switch 5 3 Variable Segments D J Constant Features: Cutoff for probe design~1-3 %* Best design for intact sections Useful for multiple translocation partners: IGH, MLL, BCL6, MYC, ALK * Cutoff values for probe types from Dewald et al, Chap 32,Clinical Laboratory Medicine, K. McClatchey Ed., F Normal 1O1G1F Abnormal

94 Gleevec

95 ES Design: One Probe Flanks, Other Probe Spans Breakpoint Cen 22 BCR Cen 9 ASS ABL Normal 2O2G Cen der(22) Fused signal Cen der(9) ASS Features: Lower cutoff for probe design ~3 %* Random chance abnormal pattern less likely Del cen to ABL breakpoint - Single Fusion *Cutoff values for probe types from Dewald et al, Chap 32, Clinical Laboratory Medicine, K. McClatchey Ed., 2002! ES signal CML nucleus Abnormal 2O1G1F

96 BCR/ABL Dual Fusion BCR/ABL Dual Fusion

97 LSI PML/RARA dual color dual fusion

98 LSI RARA BA

99 LSI MLL dual color BA

100

101

102 CMYC

103 Breast cancer! HER2/Neu amplification

104

105

106

107 Science 310: , 2005

108 Bladder Cancer: Epidemiology and Overview

109 Epidemiology #4 most common CA in Men #2 most common CA of GU Tract! 600,000 in North America living with bladder UC 57,400 new cases/year 12,500 deaths/year! Highest recurrence rate of any cancer (~70%) 30% of recurrent tumors progress American Cancer Society 2005

110 Urine Cytology

111 Cytology High Specificity Low Sensitivity Frustration high for US urologists Atypical cellularity: Recommend clinical correlation or further testing.

112 UroVysion Intended Use The UroVysion Bladder Cancer Kit (UroVysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer.! Results from the UroVysion Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for:! 1. Initial diagnosis of bladder carcinoma in patients with hematuria suspected of having BCa and subsequent! 2. Monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.!!!

113 UroVysion (p16 gene)

114 FISH Results CEP 3 (red = 2) CEP 7 (green = 2) CEP 17 (aqua = 2) LSI 9p21 (gold = 2)

115 Positive FISH DAPI CEP 3 (red = 8) CEP 7 (green = 4) CEP 17 (aqua = 3) LSI 9p21 (gold = 1)

116 LUNG CANCER ALK (anaplastic lymphoma kinase) 2p23.2 EML4 (echinoderm microtubule associated protein-like 4) 2p21! Diverse small inversions on 2p Non-small cell lung cancer Crizotinib

117 NSCLCs hybridized with the ALK break-apart FISH probe (Abbott Molecular). Camidge D R et al. Clin Cancer Res 2010;16: by American Association for Cancer Research

118 Strengths & Limitations of FISH Strengths Wide variety of tissues Metaphase & interphase Specimen structure remains intact. Cell-by-cell analysis Accommodates breakpoint variation Detects cytogenetically cryptic aberrations Contamination from previous tests not an issue Limitations Can not detect very small genetic lesions Lacks very low level detection of PCR Not as quick as rapid-cycle real-time PCR Not yet as automated as some other molecular techniques.

119 Spectral Karyotyping (SKY)

120 SKY Procedure Overview

121

122

123

124 WEB References!

125